Pentwater Capital Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1,066,200
| Closed | -$337M | – | 137 |
|
|
2023
Q4 | $337M | Buy |
1,066,200
+1,037,700
| +3,641% | +$202M | 3.78% | 7 |
|
|
2023
Q3 | $4.82M | Buy |
28,500
+1,500
| +6% | +$282K | 0.03% | 71 |
|
|
2023
Q2 | $5.85M | Sell |
27,000
-21,000
| -44% | -$4.5M | 0.04% | 76 |
|
|
2023
Q1 | $8.72M | Buy |
48,000
+38,000
| +380% | +$7.27M | 0.08% | 78 |
|
|
2022
Q4 | $1.97M | Buy |
10,000
+3,500
| +54% | +$751K | 0.03% | 87 |
|
|
2022
Q3 | $1.46M | Sell |
6,500
-23,500
| -78% | -$4.76M | 0.02% | 118 |
|
|
2022
Q2 | $3.79M | Sell |
30,000
-10,000
| -25% | -$1.15M | 0.04% | 106 |
|
|
2022
Q1 | $5.07M | Sell |
40,000
-20,000
| -33% | -$2.25M | 0.06% | 81 |
|
|
2021
Q4 | $7.86M | Sell |
60,000
-8,200
| -12% | -$1.06M | 0.09% | 77 |
|
|
2021
Q3 | $8.34M | Hold |
68,200
| – | – | 0.08% | 90 |
|
|
2021
Q2 | $7.77M | Hold |
68,200
| – | – | 0.06% | 83 |
|
|
2021
Q1 | $8.2M | Buy |
68,200
+8,200
| +14% | +$929K | 0.08% | 91 |
|
|
2020
Q4 | $6.09M | Sell |
60,000
-10,000
| -14% | -$926K | 0.07% | 71 |
|
|
2020
Q3 | $5.41M | Buy |
70,000
+23,000
| +49% | +$1.96M | 0.07% | 82 |
|
|
2020
Q2 | $5.24M | Sell |
47,000
-9,417
| -17% | -$819K | 0.09% | 52 |
|
|
2020
Q1 | $4.06M | Sell |
56,417
-1,534
| -3% | -$131K | 0.07% | 62 |
|
|
2019
Q4 | $4.37M | Sell |
57,951
-4,499
| -7% | -$197K | 0.07% | 72 |
|
|
2019
Q3 | $1.02M | Sell |
62,450
-7,550
| -11% | -$147K | 0.02% | 109 |
|
|
2019
Q2 | $1.4M | Buy |
+70,000
| New | +$1.4M | 0.02% | 125 |
|
Other funds holding KRTX
Pentwater Capital Management's KRTX Position: Q1 2024 in Review
Pentwater Capital Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 1,066,200 shares — an estimated $337M sold.
Pentwater Capital Management first reported a position in KRTX in Q2 2019 and held it in 19 quarters. The position peaked at $337M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.
- Pentwater Capital Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Pentwater Capital Management sold 1,066,200 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $337M.
- Pentwater Capital Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 19 quarters.
- Pentwater Capital Management's Karuna Therapeutics, Inc. Common Stock position peaked at $337M in Q4 2023.
- 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Pentwater Capital Management's 13F filing for Q1 2024, filed 15 May 2024.